Clinical Trial

Atorvastatin Effect on Reduction of COPD Exacerbations

Study acronym: Captain
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
It is a randomized, multicenter, prospective, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 12 Hospital Pulmonary Departments to evaluate the effectiveness of atorvastatin on the reduction of inflammation process in patients with chronic obstructive pulmonary diseases, and possible biomarkers for personalized treatment of COPD.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-03-04; most recent amendment 2026-04-16.
Status change: Recruiting → Active, Not Recruiting 2026-04-16
Status change: Not Yet Recruiting → Recruiting 2022-07-22
Trial Details
NCT Number NCT04789057
Lead Sponsor Medical University of Bialystok
Collaborators: Medical Research Agency, Poland
Conditions Copd, COPD Exacerbation, Smoking, Gene Expression, Atorvastatin
Enrollment 460 participants
Start Date 2022-02-11
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-05-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-21